Lung Cancer Biomarker Testing: EGFR, ALK, ROS1, KRAS & Why They Matter

Lung cancer is not a single disease. Two people may have cancers that look similar under a microscope but contain very different molecular changes.

These differences can matter when doctors are deciding which treatments to consider.

For certain patients—particularly those with non-small cell lung cancer (NSCLC)—biomarker testing can identify genetic or protein changes within cancer cells. Some of these biomarkers may indicate whether a targeted therapy or immunotherapy could be appropriate.

Among the biomarkers commonly discussed in lung cancer are EGFR, ALK, ROS1 and KRAS, along with several others.

So, what do these biomarkers mean, how are they tested, and why can the results be important?

What Is Lung Cancer Biomarker Testing?

Lung cancer biomarker testing examines cancer cells for specific genes, proteins or other biological characteristics.

Cancer develops when cells acquire changes that affect how they grow, divide and survive. In some lung cancers, particular molecular alterations play an important role in driving tumour growth.

Identifying these changes can provide doctors with additional information when planning treatment.

Biomarker testing may also be referred to as:

• Molecular testing
• Tumour profiling
• Genomic testing
• Molecular profiling
• Mutation testing

The exact tests required depend on the type and stage of lung cancer and the patient’s clinical circumstances.

Why Is Biomarker Testing Important in Lung Cancer?

Historically, lung cancer treatment decisions relied heavily on the cancer’s location, stage and appearance under a microscope.

These factors remain essential.

However, modern oncology can sometimes go further by examining the molecular biology of the tumour.

If testing identifies a clinically relevant alteration, doctors can determine whether an approved treatment designed to target that alteration may be suitable.

Biomarker testing may therefore help doctors:

• Identify potential targeted therapy options
• Assess whether selected immunotherapies may be appropriate
• Avoid certain treatments that are unlikely to provide the intended benefit
• Consider relevant clinical trials
• Develop a more personalised treatment strategy

Testing itself does not determine the entire treatment plan. Results must be interpreted by the treating oncology team.

Which Lung Cancer Patients May Need Biomarker Testing?

Biomarker testing is particularly important in the management of certain types of non-small cell lung cancer (NSCLC).

NSCLC accounts for the majority of lung cancer cases and includes several subtypes, such as adenocarcinoma and squamous cell carcinoma.

The recommended tests can depend on:

• The specific type of lung cancer
• Cancer stage
• Amount and quality of available tumour tissue
• Previous treatments
• Patient characteristics
• Current clinical guidelines

Not every patient requires exactly the same tests.

An oncologist or multidisciplinary cancer team determines which biomarkers are relevant for an individual patient.

What Is an EGFR Mutation?

EGFR stands for epidermal growth factor receptor.

The EGFR gene provides instructions for producing a protein involved in cell growth and survival.

Some lung cancer cells develop mutations in EGFR that cause the signalling pathway to remain abnormally active. This can encourage cancer cells to continue growing.

When an appropriate EGFR mutation is identified, doctors may consider medicines known as EGFR tyrosine kinase inhibitors (TKIs).

Different EGFR mutations can have different treatment implications, so the exact laboratory result matters.

What Is an ALK Rearrangement?

ALK stands for anaplastic lymphoma kinase.

In some lung cancers, part of the ALK gene becomes joined with another gene. This can create an abnormal fusion protein that promotes cancer growth.

These changes are generally known as ALK rearrangements or ALK fusions.

If an actionable ALK alteration is identified, an ALK-targeted medicine may be considered depending on the patient’s clinical situation.

This is an example of how identifying a molecular driver can directly influence treatment planning.

What Is a ROS1 Rearrangement?

ROS1 is another gene involved in cell signalling.

In a small proportion of non-small cell lung cancers, ROS1 can become fused with another gene.

The resulting abnormal signalling may contribute to uncontrolled cancer-cell growth.

When a clinically relevant ROS1 fusion is identified, doctors may evaluate treatments specifically designed to inhibit this pathway.

Although ROS1 alterations are relatively uncommon, identifying them can be important because targeted treatment options may be available.

What Is a KRAS Mutation?

KRAS is a gene involved in signalling pathways that regulate cell growth.

KRAS mutations are found in a proportion of non-small cell lung cancers.

For many years, KRAS was considered a particularly difficult cancer target. Advances in drug development have now produced targeted medicines for certain KRAS alterations, including KRAS G12C, in appropriate clinical settings.

However, not every KRAS mutation is the same.

A laboratory report should therefore identify the specific alteration rather than simply stating that KRAS is positive.

What Other Biomarkers May Be Tested?

EGFR, ALK, ROS1 and KRAS are important, but they are not the only biomarkers relevant to lung cancer.

Depending on the patient’s diagnosis and current treatment guidelines, testing may also evaluate alterations involving genes or proteins such as:

• BRAF
• MET
• RET
• NTRK
• HER2
• PD-L1

Additional biomarkers continue to be investigated as cancer research advances.

This is one reason broader molecular testing methods are increasingly important in modern oncology.

What Is PD-L1 Testing?

PD-L1 testing is different from testing for mutations such as EGFR or KRAS.

PD-L1 is a protein that can help cancer cells reduce immune-system activity.

Doctors may measure the level of PD-L1 expression in tumour cells to help evaluate whether certain immunotherapy approaches could be appropriate.

However, PD-L1 is only one part of treatment decision-making.

The significance of a PD-L1 result depends on the cancer, other biomarker findings, disease stage and the treatment strategy being considered.

How Is Lung Cancer Biomarker Testing Performed?

There are several ways doctors can obtain material for molecular testing.

Tissue Biopsy

A sample of the tumour may be obtained during a biopsy or surgical procedure.

The laboratory can examine this tissue to confirm the diagnosis and perform relevant biomarker tests.

Next-Generation Sequencing (NGS)

Next-generation sequencing can analyse multiple genes within a tumour sample.

Instead of testing genes individually, an NGS panel may allow laboratories to investigate several potentially relevant molecular alterations at the same time.

The exact genes included depend on the test.

Liquid Biopsy

In selected situations, doctors may use a liquid biopsy.

This involves analysing cancer-related material—particularly circulating tumour DNA (ctDNA)—found in the bloodstream.

A liquid biopsy may help identify certain mutations when appropriate.

However, not every cancer releases enough detectable DNA into the blood.

Therefore, a negative liquid biopsy does not always rule out the presence of a molecular alteration, and tissue testing may still be required.

What Happens If a Biomarker Is Found?

Finding a biomarker is not automatically the same as finding a treatment.

Doctors first need to determine whether the identified alteration is clinically actionable.

They may consider:

• Whether an approved medicine targets the alteration
• Evidence supporting treatment in that particular lung cancer
• Stage of the cancer
• Previous treatment
• Other biomarker results
• Potential treatment side effects
• Overall patient health

In some situations, a biomarker may also help identify a potentially relevant clinical trial.

What Happens If No Actionable Biomarker Is Found?

Not finding an actionable molecular alteration does not mean that there are no treatment options.

Depending on the patient’s cancer and overall condition, treatment may still involve:

• Surgery
• Radiation therapy
• Chemotherapy
• Immunotherapy
• Combination treatment
• Other systemic treatments

Cancer treatment depends on much more than a single laboratory test.

The oncology team combines pathology, imaging, biomarker results and clinical information to develop an appropriate treatment strategy.

Can Lung Cancer Biomarkers Change Over Time?

Yes.

Cancer cells can evolve, particularly under the pressure of treatment.

A tumour that initially responds to targeted therapy may eventually develop additional molecular changes that allow some cancer cells to survive.

This process is one cause of treatment resistance.

If a cancer begins progressing, doctors may sometimes recommend additional testing.

This could involve a new tissue biopsy, liquid biopsy or another molecular investigation.

The purpose is to understand whether the cancer has developed a new alteration that could influence the next treatment decision.

Biomarker Testing vs Genetic Testing: Are They the Same?

Not always.

This distinction is important.

Tumour biomarker testing generally looks for molecular changes present within cancer cells. Many of these changes developed during a person’s lifetime and are not inherited.

Inherited genetic testing, also known as germline testing, looks for genetic changes a person was born with and which may potentially be passed through families.

The two types of testing can sometimes overlap, but they answer different medical questions.

Patients should ask their healthcare team what type of genetic or molecular testing is being recommended and why.

Frequently Asked Questions About Lung Cancer Biomarker Testing

Does every lung cancer patient need biomarker testing?

Not necessarily. The recommended testing depends on the type and stage of lung cancer and the clinical situation.

Can a blood test identify lung cancer mutations?

In selected situations, liquid biopsy can detect certain tumour-related genetic alterations in blood. However, a negative blood result does not always rule out a mutation.

What does EGFR-positive lung cancer mean?

It generally means that testing has identified an EGFR alteration in the cancer. The exact mutation is important because different alterations can have different treatment implications.

What does ALK-positive lung cancer mean?

It usually refers to a lung cancer containing a clinically relevant ALK rearrangement or fusion. Certain ALK-targeted treatments may be considered depending on the clinical situation.

Can targeted therapy cure lung cancer?

Targeted therapy is not a universal cure. Some patients can experience significant and sometimes prolonged responses, but outcomes vary.

Can lung cancer become resistant to targeted therapy?

Yes. Cancer cells can develop additional molecular changes over time that allow them to grow despite treatment. Doctors may consider repeat molecular testing when resistance develops.

Conclusion

Lung cancer biomarker testing has become an important part of personalised cancer care.

By examining molecular changes such as EGFR, ALK, ROS1 and KRAS, doctors may gain information that helps them evaluate targeted treatments and other therapeutic options.

However, biomarker testing is only one part of cancer care. Results must be interpreted alongside the patient’s diagnosis, cancer stage, overall health and treatment history.

At Galaxy Super Speciality, we aim to make complex developments in cancer treatment easier for patients and families to understand.

Patients should always discuss biomarker testing and treatment decisions with a qualified oncologist.

Medical Disclaimer: This article is for general educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment.

SEO Settings for WordPress

SEO Title:
Lung Cancer Biomarker Testing: EGFR, ALK, ROS1 & KRAS

Focus Keyphrase:
lung cancer biomarker testing

Secondary Keywords:
lung cancer genetic testing
EGFR mutation lung cancer
ALK positive lung cancer
ROS1 lung cancer
KRAS mutation lung cancer
NSCLC biomarker testing
lung cancer molecular testing
targeted therapy for lung cancer

URL Slug:
lung-cancer-biomarker-testing

Meta Description:
Learn how lung cancer biomarker testing identifies EGFR, ALK, ROS1, KRAS and other molecular changes that may help doctors guide treatment.

Category:
Cancer / Oncology

Suggested Featured Image Alt Text:
Lung cancer biomarker testing illustration showing EGFR, ALK, ROS1 and KRAS molecular testing for personalised treatment.

Suggested Internal Links:
Cancer Biomarker Testing
Targeted Therapy for Cancer
Liquid Biopsy for Cancer
Cancer Immunotherapy
Precision Oncology